Iovance Biotherapeutics annual gross margin
2023
2024
2025
Iovance Biotherapeutics Gross Margin Growth & History (IOVA)
Iovance Biotherapeutics's gross margin was 34.28% for fiscal 2025.
View full Iovance Biotherapeutics company overviewIovance Biotherapeutics annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 34.28% | −8.89 pp |
| 2024 | 2024-12-31 | 43.17% | +30.05 pp |
| 2023 | 2023-12-31 | 13.12% | — |
Iovance Biotherapeutics quarterly gross margin
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 56.10% | +37.64 pp |
| Q1 2026 | 2026-03-31 | 40.50% | +27.10 pp |
| Q4 2025 | 2025-12-31 | 50.32% | −18.34 pp |
| Q3 2025 | 2025-09-30 | 42.96% | −3.21 pp |
| Q2 2025 | 2025-06-30 | 18.47% | +19.31 pp |
| Q1 2025 | 2025-03-31 | 13.40% | +928.92 pp |
| Q4 2024 | 2024-12-31 | 68.65% | — |
| Q3 2024 | 2024-09-30 | 46.17% | +871.55 pp |
| Q2 2024 | 2024-06-30 | −0.84% | +760.50 pp |
| Q1 2024 | 2024-03-31 | −915.52% | — |
| Q3 2023 | 2023-09-30 | −825.37% | — |
| Q2 2023 | 2023-06-30 | −761.34% | — |
Iovance Biotherapeutics gross margin trends
Between the periods ended 2023-12-31 and 2025-12-31, Iovance Biotherapeutics's gross margin increased from 13.12% to 34.28%, a change of +21.16 percentage points. The latest reported quarter, Q2 2026, shows 56.10%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Iovance Biotherapeutics source filings ↗